Syracuse

Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria?

Archive ouverte

Pozdzik, Agnieszka | David, Cristina | Vekeman, Jelle | Tielens, Frederik | Daudon, Michel

Edité par CCSD ; Wiley -

International audience. Introduction: The therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required. Case presentation: A 37-year-old hemodialyzed man suffered from systemic oxalosis secondary to primary hyperoxaluria type 1 exhibited a drastic plasma oxalate decrease from 110 to 22 µmol/L two months after adjunction of lanthanum carbonate to classical treatment (intensive hemodialysis with pyridoxine). A 34-year-old woman with normal kidney function presented 10 years of bilateral kidney stones due to primary hyperoxaluria type 1 [hyperoxaluria (109.2 mg/24 h), plasma oxalate (56.0 µmol/L)]. The oxalate level remained uncontrolled despite of low oxalate-normal calcium diet, pyridoxine and increased water intake though the lanthanum carbonate adjunction resulted in significant decrease in plasma oxalate and oxaluria. Conclusion: We report the lanthanum efficacy in reducing circulating and urinary oxalate levels in type 1 primary hyperoxaluria. Possible mechanism of observed falls in oxalate concentration would be a decrease in the intestinal absorption of oxalate.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion